Vertex Ventures HC Announces Christine Brennan, Ph.D., Appointed to BIO Board of Directors

Boston, 3rd December 2024 – Vertex Ventures HC (VVHC), a leading global healthcare investment firm, is pleased to share that Christine Brennan, Ph.D., Managing Director, has been appointed to the Board of Directors of the Biotechnology Innovation Organization (BIO). In this role, she will also serve on the Emerging Companies Section Governing Board.

BIO is the world's largest biotechnology advocacy association, representing member companies, academic institutions and research institutions, as well as other related organizations across the United States and in over 30 countries worldwide. It focuses on advancing the biotechnology industry through the pursuit of partnerships and enhanced connectivity while also spearheading the BIO International Convention – the largest global event for the biotechnology sector. Dr. Brennan brings over 20 years of experience in the life sciences industry to her new role on the BIO Board. Her expertise spans across business development, corporate strategy, and venture investing – making her a valuable addition to BIO's leadership.

“BIO plays a pivotal role in advancing innovation in biotechnology on a global scale and I am honored and excited to represent Vertex Ventures HC and help drive our shared mission of progressing science towards delivering innovative medicines for the patients,” said Christine Brennan. “As a member of BIO’s board of directors, I will continue to champion scientific innovation that puts the patient first.”

Dr. Brennan joined Vertex Ventures HC as a Managing Director in February 2022, where she has been instrumental in driving the firm's investment strategy in transformative healthcare innovations. Prior to VVHC, she was a Partner at Merck Research Labs (MRL) Ventures Fund and held a Principal position at the Novartis Venture Fund.

Her appointment to the BIO Board of Directors further solidifies Vertex Ventures HC's position as a key player in the biotechnology investment landscape and underscores the firm's commitment to driving innovation in healthcare.

 

About Vertex Ventures HC
Established in 2014, Vertex Ventures HC (VVHC) is a global healthcare venture capital firm investing in life sciences companies to develop new medicines that all families need now and in the future. Since its founding, VVHC has USD 400M assets under management and invested in more than 25 portfolio companies to bring transformative therapies and healthcare technologies to patients, including more than 20 clinical-stage assets and three products cleared by the US Food and Drug Administration (FDA). VVHC has offices in San Francisco, CA and Boston, MA.

For more information, please visit www.vertexventureshc.com

 

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

 For more information, please visit https://www.bio.org/

 

For Media Inquiries

Bernice Ong, Vertex Holdings
bmyong@vertexholdings.com